HCTI Seeks Shareholder Nod for $70M Capital Raise

TL;DR

**HCTI is asking shareholders to approve massive dilution for working capital, which is a huge red flag for current investors.**

AI Summary

Healthcare Triangle, Inc. (HCTI) is seeking stockholder approval for future security issuances totaling up to $70 million, as outlined in its DEF 14A filing on November 17, 2025. This proposal, known as the Nasdaq Approval Proposal, is crucial for the company to raise additional working capital. The issuances, which can occur between November 14, 2025, and February 28, 2026, are subject to specific Nasdaq Parameters: a maximum of 50,000,000 shares of common stock, 100,000,000 shares upon warrant exercise, and a maximum dollar amount of $25,000,000 per issuance, with a maximum discount of 80% to the market price. The Special Meeting of Stockholders, scheduled virtually for November 28, 2025, at 10:00 a.m. Pacific Time, will address this single proposal. The Board of Directors unanimously recommends a 'FOR' vote, emphasizing the need for capital to support ongoing operations. As of the record date, November 12, 2025, there were 7,261,344 shares of common stock and 20,000 shares of Series A Super Voting Preferred Stock outstanding, with the latter carrying 1,000 votes per share.

Why It Matters

This DEF 14A filing is critical for HCTI investors as it directly impacts potential dilution and the company's ability to secure necessary working capital. Approval of the $70 million future issuance allows HCTI to fund operations and strategic initiatives, potentially stabilizing its financial position. However, the proposed 80% discount to market price for issuances could significantly dilute existing shareholder value, making it a high-stakes vote. In a competitive healthcare technology market, access to capital is paramount for innovation and growth, and this proposal will determine HCTI's financial flexibility against rivals.

Risk Assessment

Risk Level: high — The proposal allows for future issuances up to $70 million with a 'Maximum Amount of discount to the market: 80%'. This significant discount, combined with a potential issuance of up to 50,000,000 shares of common stock and 100,000,000 shares upon warrant exercise, indicates a very high risk of substantial dilution for existing shareholders, severely impacting their ownership percentage and share value.

Analyst Insight

Investors should carefully evaluate the potential for extreme dilution given the 80% discount and large share issuance limits. Consider voting 'AGAINST' the Nasdaq Approval Proposal if you are concerned about protecting your current equity stake, or demand more favorable terms from the company.

Key Numbers

• $70M — Aggregate Future Issuances (Maximum capital to be raised through security issuances)
• 50,000,000 — Max Common Shares Issuable (Potential dilution from common stock issuance)
• 100,000,000 — Max Warrant Shares Issuable (Potential dilution from warrant exercise)
• 80% — Max Discount to Market (Significant potential discount for future security sales)
• 7,261,344 — Common Stock Outstanding (Shares outstanding as of November 12, 2025 record date)
• 20,000 — Series A Super Voting Preferred Stock Outstanding (Shares outstanding with 1,000 votes per share)
• 10:00 a.m. PT — Special Meeting Time (Time of the virtual stockholder meeting on November 28, 2025)
• November 12, 2025 — Record Date (Date for determining stockholders entitled to vote)
• February 28, 2026 — Issuance Deadline (Latest date for completing approved future issuances)
• 1,000 — Votes per Series A Preferred Share (Voting power of Series A Super Voting Preferred Stock)

Key Players & Entities

• Healthcare Triangle, Inc. (company) — Registrant seeking stockholder approval
• Nasdaq (regulator) — Exchange requiring stockholder approval under Listing Rule 5635(d)
• David Ayanoglou (person) — Chief Financial Officer of Healthcare Triangle, Inc.
• Dave Rosa (person) — Chairman of the Board of Healthcare Triangle, Inc.
• Alliance Advisors (company) — Contact for stockholder voting questions
• $70 million (dollar_amount) — Aggregate maximum for future security issuances
• 50,000,000 (dollar_amount) — Maximum number of common shares issuable per future issuance
• 100,000,000 (dollar_amount) — Maximum number of shares issuable upon exercise of warrants per future issuance
• $25,000,000 (dollar_amount) — Maximum dollar amount per future issuance
• 80% (dollar_amount) — Maximum discount to market price for future issuances

FAQ

Risk Factors

• Reliance on Future Capital Infusions [high — financial]: The company is seeking approval for future security issuances totaling up to $70 million to raise additional working capital. This reliance on external financing, particularly through discounted issuances (up to 80% discount to market price), indicates potential financial distress or a need to fund operations and growth initiatives that current cash flows cannot support. The ability to secure this capital is critical for ongoing operations.
• Nasdaq Listing Rule Compliance [high — regulatory]: The primary purpose of the Special Meeting is to obtain stockholder approval for issuances of securities that may exceed Nasdaq's standard limits without shareholder approval, specifically under Nasdaq Listing Rule 5635(d). Failure to secure this approval could restrict the company's ability to raise necessary capital, potentially impacting its listing status or operational capacity.
• Potential for Significant Dilution [high — financial]: The proposed issuances could lead to substantial dilution for existing shareholders. The company can issue up to 50,000,000 shares of common stock and an additional 100,000,000 shares upon warrant exercise, in addition to other potential securities, all within a $70 million aggregate limit. This large potential increase in outstanding shares, especially if issued at a significant discount, could severely impact the value of existing holdings.
• Market Price Sensitivity [medium — market]: The company is permitted to issue securities at a discount of up to 80% to the market price. This provision suggests that the company may need to offer highly attractive terms to secure funding, potentially reflecting current market sentiment towards its stock or the perceived risk associated with its business. Significant discounts can erode shareholder value rapidly.

Industry Context

Healthcare Triangle, Inc. operates within the healthcare technology sector, which is characterized by rapid innovation, evolving regulatory landscapes, and significant capital requirements for research, development, and market penetration. Companies in this space often rely on external funding to fuel growth and navigate competitive pressures. The need for capital to support ongoing operations suggests potential challenges in generating sufficient internal cash flow.

Regulatory Implications

The primary regulatory implication is the need to comply with Nasdaq Listing Rule 5635(d), which requires shareholder approval for certain equity issuances. Obtaining this approval is critical for Healthcare Triangle, Inc. to execute its capital-raising strategy. Failure to secure approval could lead to limitations on the company's ability to raise funds, potentially impacting its operational continuity and compliance with listing standards.

What Investors Should Do

1. Review the potential dilution from the proposed security issuances, considering the maximum number of shares (50,000,000 common, 100,000,000 warrant shares) and the potential for significant discounts (up to 80%) when deciding how to vote.
2. Assess the company's financial health and the necessity of raising up to $70 million in capital, understanding that this funding is critical for ongoing operations.
3. Consider the voting power of the Series A Super Voting Preferred Stock (1,000 votes per share) and its potential impact on the outcome of the Nasdaq Approval Proposal, as it votes with common stock as a single class.
4. Vote 'FOR' the Nasdaq Approval Proposal if you believe the capital infusion is essential for the company's survival and future prospects, despite the risks of dilution and discounted issuance.

Key Dates

• 2025-11-12: Record Date — Determines which stockholders are entitled to vote at the Special Meeting.
• 2025-11-17: Proxy Materials Mailed — Date when stockholders began receiving notice and access to proxy materials for the Special Meeting.
• 2025-11-28: Special Meeting of Stockholders — Date for stockholders to vote on the Nasdaq Approval Proposal.
• 2025-11-14: Start of Future Issuance Period — The earliest date that approved future security issuances can be completed.
• 2026-02-28: Issuance Deadline — The latest date by which the approved future security issuances must be completed.

Glossary

DEF 14A

A Definitive Proxy Statement filed with the SEC by a company to solicit proxies from its shareholders for an upcoming meeting. (This document outlines the proposals to be voted on, including the Nasdaq Approval Proposal, and provides background information for shareholders.)

Nasdaq Approval Proposal

A proposal requiring stockholder approval for issuances of securities that are completed within a specific period and aggregate dollar amount, subject to certain parameters, to comply with Nasdaq Listing Rule 5635(d). (This is the sole proposal to be voted on at the Special Meeting, crucial for the company's ability to raise capital.)

Nasdaq Parameters

Specific limits set by Nasdaq for security issuances, including maximum shares of common stock, shares issuable upon warrant exercise, dollar amount of issuance, and maximum discount to market price. (These parameters define the conditions under which the company can issue securities without further shareholder approval beyond this proposal.)

Series A Super Voting Preferred Stock

A class of preferred stock with significantly enhanced voting rights, in this case, 1,000 votes per share. (The existence of this class of stock, though small in number (20,000 shares), has a disproportionately large voting impact (20,000,000 votes) compared to common stock.)

Working Capital

The difference between a company's current assets and current liabilities, representing the funds available for day-to-day operations. (The company explicitly states the purpose of the proposed issuances is to raise additional working capital, highlighting its need for operational funds.)

Year-Over-Year Comparison

This filing is a proxy statement for a special meeting, not an annual report, and therefore does not contain comparative financial data from a previous year. The focus is on a specific proposal to authorize future security issuances totaling up to $70 million, which is a forward-looking request for capital rather than a review of past performance.

Key Financial Figures

• $70 million — 8, 2026 that are in the aggregate up to $70 million (“Future Issuances”), as lo
• $25,000,000 — 3. Maximum Dollar Amount of Issuance: $25,000,000. 4. Maximum Amount of discount to the
• $0.00001 — 4 shares of our common stock, par value $0.00001 per share, and 20,000 shares of the Ser
• $70 M — 8, 2026 THAT ARE IN THE AGGREGATE UP TO $70 MILLION, AS LONG AS EACH FUTURE ISSUNACE

Filing Documents

• ea0265538-def14a_health.htm (DEF 14A) — 110KB
• image_001.jpg (GRAPHIC) — 685KB
• image_002.jpg (GRAPHIC) — 274KB
• 0001213900-25-111526.txt ( ) — 1432KB

SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS

SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT The following table sets forth information with respect to the beneficial ownership of our common stock and our Series A Super Voting Preferred Stock, our only outstanding classes of capital stock having the right to vote on this matter, known by us as of the Record Date, by: each person or entity known by us to be the beneficial owner of more than 5% of our common stock; each of our directors; each of our executive officers; and all of our directors and executive officers as a group. Beneficial ownership of the voting stock is determined in accordance with the rules of the United States Securities and Exchange Commission (the “ SEC ”) and includes any shares of Company voting stock over which a person exercises sole or shared voting or investment power, or of which a person has a right to acquire ownership at any time within 60 days of November 12, 2025. Except as otherwise indicated, we believe that the persons named in this table have sole voting and investment power with respect to all shares of voting stock held by them. Applicable percentage ownership in the following table is based on 7,261,344 shares of our common stock and 20,000 shares of our Series A Super Voting preferred stock issued and outstanding on November 12, 2025. Except as otherwise indicated, the persons listed below have sole voting and investment power with respect to all shares of our common stock owned by them, except to the extent such power may be shared with a spouse. To our knowledge, none of the shares listed below are held under a voting trust or similar agreement, except as noted. To our knowledge, there is no arrangement, including any pledge by any person of securities of the Company, the operation of which may at a subsequent date result in a change in control of the Company. Number of Shares Beneficially Owned Beneficial Ownership Percentages Name and Address of Beneficial Owner (1) Title

View Full Filing

View this DEF 14A filing on SEC EDGAR